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http://dx.doi.org/10.1016/j.ccr.2013.07.012SUMMARYIn contrast to its close homolog CDK4, the cell cycle kinase CDK6 is expressed at high levels in lymphoid
malignancies. In a model for p185BCR-ABL+ B-acute lymphoid leukemia, we show that CDK6 is part of a tran-
scriptioncomplex that induces theexpressionof the tumor suppressorp16INK4a and thepro-angiogenic factor
VEGF-A. This function is independent of CDK6’s kinase activity. High CDK6 expression thus suppresses pro-
liferation by upregulating p16INK4a, providing an internal safeguard. However, in the absence of p16INK4a,
CDK6 can exert its full tumor-promoting function by enhancing proliferation and stimulating angiogenesis.
The finding that CDK6 connects cell-cycle progression to angiogenesis confirms CDK6’s central role in he-
matopoieticmalignancies and could underlie the selection pressure to upregulate CDK6 and silence p16INK4a.INTRODUCTION
Cell cycle deregulation is a common feature of human cancer
(Cordon-Cardo, 1995; Deshpande et al., 2005; Kim and Diehl,Significance
Aberrant growth control is one hallmark of cancer cells. The cyc
and is expressed at high levels in lymphoid tumors.Wepresent
that is unrelated to its kinase activity. Part of the CDK6-depend
genesis and controls de novo formation of blood vessels. CDK
also ensuring the supply of oxygen and energy to the tumor. A
kinase-dependent functions. Our insights may reshape future
neous inhibition of cell-cycle progression and CDK6’s other, k2009; Malumbres and Barbacid, 2001). Accordingly, cell-cycle
kinases represent promising targets for the development of
low-molecular-weight compounds for use in cancer therapy
(Cicenas and Valius, 2011; Malumbres, 2012). Cyclin dependentlin-dependent kinaseCDK6promotes cell-cycle progression
evidence for a function of CDK6 as a transcriptional regulator
ent gene signature is VEGF-A, which promotes tumor angio-
6 thus represents a factor that regulates tumor growth while
vailable anticancer drugs targeting CDK6 focus on CDK6’s
strategies to develop CDK6 inhibitors, allowing the simulta-
inase-independent functions.
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CDK6 and Angiogenesiskinases (Cdks) belong to the core cell-cycle machinery and
comprise a family of serine/threonine kinases that exert their cat-
alytic activity when bound to their partners, the cyclins (Sherr and
Roberts, 1999). The close homologs CDK4 and CDK6 are ubiq-
uitously expressed. They bind D-type cyclins and are then able
to phosphorylate the retinoblastoma protein to relieve the tran-
scriptional repression of E2F-dependent genes, thereby driving
cells through the G1 phase into the S phase of the cell cycle
(Classon and Harlow, 2002; Ekholm and Reed, 2000; Matsush-
ime et al., 1994). Experiments with gene-deficient mice have
facilitated the elucidation of partially overlapping and redundant
physiologic roles for CDK4 and CDK6. Apart from minor tissue-
specific abnormalities, Cdk4 and Cdk6 single knockout mice
are viable and fertile (Malumbres et al., 2004; Zou et al., 2002).
The deletion of both Cdk4 and Cdk6 induces late embryonic
lethality due to defects in hematopoiesis (Kozar and Sicinski,
2005; Malumbres et al., 2004).
Cell-cycle inhibitors block cell-cycle progression by binding
and inhibiting cell-cycle kinases. The CDK4- and CDK6-cyclin D
complexes are subject to inhibition by p21cip and p27kip. In addi-
tion, the INK4 family members (p16INK4a, p15INK4b, p18INK4c,
p19INK4d) inhibit monomeric CDK4 and CDK6 and thus prevent
complex formation with cognate cyclins (Ca´nepa et al., 2007;
Pavletich, 1999; Sherr and Roberts, 1999; Vidal and Koff, 2000).
Cell-cycle components are frequently altered or mutated in
human cancer, reflecting the deregulated growth of transformed
cells. Mutations in exon 2 of CDK4 have been related to heredi-
tary melanoma (Bressac-de-Paillerets et al., 2002; Goldstein
et al., 2006; Wo¨lfel et al., 1995). Recently, two novel mutations
in the N-terminal domain of CDK4 were related to head and
neck cancer (Sabir et al., 2012). CDK4 has also been character-
ized as an essential component for c-neu/ERBB-2-induced
breast cancer (Landis et al., 2006).Cdk4/ breast tissue is indis-
tinguishable from the normal mouse mammary gland; however,
c-neu/ERBB-2-dependent tumor development is completely
abrogated in the absence of CDK4 (Landis et al., 2006; Malum-
bres and Barbacid, 2006; Reddy et al., 2005). No mutations in
human CDK6 have been identified, although enhanced CDK6
expression has been documented in lymphoma and leukemia
(Chilosi et al., 1998; Lien et al., 2000; Nagel et al., 2008; Schwartz
et al., 2006), and several reports have documented chromo-
somal translocations in patients suffering from B-lymphoid
malignancies involving CDK6. In these patients, the aberrant
and increased expression of CDK6 has been proposed to be
the cause and/or driving force for the disease (Brito-Babapulle
et al., 2002; Chen et al., 2009; Hayette et al., 2003; Parker
et al., 2012). In addition, recent papers describe altered micro-
RNA regulation (i.e., miR-124a, miR-29) resulting in an upregula-
tion of CDK6 in lymphoid malignancies (Agirre et al., 2009;
Rodriguez-Otero et al., 2011; Wong et al., 2011; Zhao et al.,
2010). Nevertheless, there is still no formal proof that CDK6
has a role in initiating B-lymphoid leukemia or in driving the
expansion of a leukemic clone.
CDK6 has also been implicated in thymic lymphoma formation
in a transgenic mousemodel in which lymphoma development is
triggered by a constitutively active AKT. In this particular setting,
lymphomas did not develop in the absence of CDK6 (Hu et al.,
2009). We have shown that loss of the AP-1 transcription
factor JUNB—as frequently observed in human leukemia (Mao168 Cancer Cell 24, 167–181, August 12, 2013 ª2013 Elsevier Inc.et al., 2003; Yang et al., 2003) - is associated with more aggres-
sive disease and a significantly accelerated progression of
p185BCR-ABL-induced leukemia (Szremska et al., 2003). The
expression of CDK6 is consistently elevated in the highly malig-
nant JunB deficient cells (Ott et al., 2007). In line with this, the
lack of c-JUN, an antagonist of JUNB, leads to the down-
regulation of CDK6 and as a result to reduced proliferation of
p185BCR-ABL-transformed cells as well as to prolonged disease
onset. The data were confirmed by using the Cdk6/ mouse
in a p185BCR-ABL leukemia model (Kollmann et al., 2011a).
Together with the reports of elevated CDK6 protein levels in
human disease, these findings prompted us to investigate the
role of CDK6 in lymphoid malignancies.
RESULTS
Forced CDK6 Expression Suppresses Tumor Formation
To investigate the consequences of increasing CDK6 expres-
sion in B-lymphoid leukemia/lymphoma, we generated stable
p185BCR-ABL-transformed pro B cell lines. These were infected
with either a pMSCV-puro (Cdk6+/+) or a pMSCV-Cdk6-puro
based retrovirus (Cdk6+/++Cdk6). Contrary to our expectations,
Cdk6+/++Cdk6 cells displayed a strong reduction of proliferation
(confirmed by three different experimental techniques, see Fig-
ure 1A; Figures S1A–S1C available online). Moreover, cells with
high CDK6 levels formed fewer and smaller colonies in growth
factor-free methylcellulose (Figure 1B). We did not find any in-
crease in apoptosis or any signs of senescence on inducing
CDK6 expression (Figures S1D–S1F and data not shown). No
major changes in subcellular localization of CDK6were observed
upon enforced expression (Figure S1G). Consistently with their
in vitro phenotype, Cdk6+/++Cdk6 cells gave rise to subcutane-
ous lymphoma-like tumors or leukemia with increased latency
(Figures 1C and 1D). We confirmed the reduced proliferation of
Cdk6+/++Cdk6 cells in vivo by staining subcutaneous tumor
sections for the proliferation marker Ki-67 (Figures 1E and 1F).
These experiments are in line with a tumor-suppressing function
of CDK6.
CDK6 Acts as a Transcriptional Regulator
on the p16INK4a Promoter
To investigate the underlying mechanism, we examined the
expression of several genes known to be important for cell-cycle
control. Elevated CDK6 expression was consistently accompa-
niedbyhigh levelsof thecell-cycle inhibitor and tumorsuppressor
p16INK4a, while protein levels of other members of the INK4
family (p15INK4b, p18INK4c, p19INK4d), p19ARF as well as p21CIP1
and p27KIP1 remained unchanged or were hardly expressed at
all (Figure 2A; Figures S2A andS2B). These findingswere recapit-
ulated inmurineembryonic fibroblasts (MEFs) that hadnot yet un-
dergonesenescence (FigureS2C). Theupregulationof p16INK4a is
not caused by increased protein stability as it persisted upon
treatment with the proteasome inhibitor bortezomib (Figure S2D).
In contrast to CDK6, high expression of CDK4 in p185BCR-ABL+
leukemic cells did not increase p16INK4a expression, nor was
any change in tumor growth observed (Figures S2E–S2H).
Enforced expression of CDK6 led to a pronounced increase
in the levels of p16INK4a mRNA and pre-mRNA (Figure 2B; Fig-
ure S2I), indicating a role for CDK6 in regulating the transcription
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Figure 1. Enforced Expression of CDK6 in p185BCR-ABL-Transformed Cells Unmasks Its Tumor-Suppressing Activity
(A) 3[H]-thymidine incorporation of Cdk6+/+ (expressing a pMSCV-puro-based retrovirus) and Cdk6+/++Cdk6 (expressing a pMSCV-Cdk6-puro-based retrovirus)
p185BCR-ABL-transformed cells (n = 4; **p = 0.009).
(B) Colony-forming assays were performed by seeding a defined number of p185BCR-ABL-transformed Cdk6+/+ or Cdk6+/++Cdk6 cells in growth factor-free
methylcellulose. Left side: representative set of pictures. Right side: number of colonies per dish after incubation for 5 days (n = 4/genotype; *p = 0.023).
(C) Kaplan-Meier plot ofNu/Numice injected subcutaneously withCdk6+/+ orCdk6+/++Cdk6 cells (n = 4 cell lines/genotype; n = 2mice/cell line; mean survival: 18
[Cdk6+/+] versus 26 [Cdk6+/++Cdk6] days; **p = 0.002).
(D) Kaplan-Meier plot of Rag2/ mice transplanted intravenously with Cdk6+/+ or Cdk6+/++Cdk6 cells (n = 3 cell lines/genotype; n = 6 mice/genotype; mean
survival: 18 [Cdk6+/+] and 29 [Cdk6+/++Cdk6] days; *p = 0.014).
(E and F) Immunohistochemical stainings for the proliferation marker Ki-67 of Cdk6+/+ (n = 4) and Cdk6+/++Cdk6 (n = 9) tumors were quantified with HistoQuest
software. A representative set of pictures is given (E). Original magnification 203. Bar graphs depict percentage of Ki-67-positive tumor cells (F; p = 0.029 [*]).
Error bars indicate the mean ± SEM. See also Figure S1.
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CDK6 and Angiogenesisof p16INK4a. In line with this, expression of CDK6 in p185BCR-ABL-
transformed Cdk6/ cell lines resulted in a p16INK4a upregula-
tion as well as a decreased proliferation (Figures S2J–S2L).
The generation of p185BCR-ABL-transformed Cdk6/ cells ex-
pressing a doxycycline-inducible CDK6 construct showed that
the induction of p16INK4a occurs at concentrations that are within
a physiologic range (Figure 2C). Chromatin immunoprecipitation(ChIP) experiments revealed that CDK6 binds specifically to the
p16INK4a promoter, while no binding to the p19ARF promoter was
detected (Figure 2D; Figure S6I). These findings define CDK6 as
part of a transcriptional complex that regulates the tumor sup-
pressor p16INK4a. In line with this finding, we detected the loss
of the inhibitory histone mark H3K27me3, which controls
p16INK4a expression (Figure 2E; Agger et al., 2009; BarradasCancer Cell 24, 167–181, August 12, 2013 ª2013 Elsevier Inc. 169
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Figure 2. CDK6 Acts as a Transcriptional Regulator of p16INK4a
(A) Immunoblot for CDK6 and p16INK4a of three individually derived Cdk6+/+ cell lines with (+Cdk6) or without (w/o vector, empty vector) enforced CDK6
expression.
(B) p16INK4a mRNA levels of Cdk6+/+ and Cdk6+/++Cdk6 cells were analyzed with qPCR (n = 6; *p = 0.03).
(C) Immunoblot for CDK6 and p16INK4a of Cdk6/ cells expressing a doxycycline-inducible tet-on Cdk6 vector (Cdk6/+tet-on Cdk6). Lane 1: Cdk6/ cells.
Lanes 2–5: Cdk6/+tet-on Cdk6 cells 48 hr after treatment with doxycycline (0, 0.3, 1, 3 mM). Lane 6: Cdk6+/+ cells. Lane 7: Cdk6+/++Cdk6 cells.
(D) ChIP assays were performed using Cdk6+/++Cdk6 and Cdk6/ cells. Protein-DNA complexes were immunoprecipitated using an anti-CDK6-antibody and
analyzed by PCR for the presence of p16INK4a and as specificity control of ARF promoter sequence (region depicted in Figure 2F as open rectangles).
(E) Promoter ChIP assays were performed usingCdk6+/+,Cdk6+/++Cdk6, andCdk6/ cells. Protein-DNA complexes were immunoprecipitated using antibodies
specific for the indicated histone modification. ChIP DNA was analyzed with qPCR for the presence of a p16INK4a promoter sequence (region 1 in Figure 2F). The
relative enrichment to a control region is shown (Tbp promoter for H3K9ac, H3K4me2, and H3K4me3; Neurog1 promoter for H3K27me3). The mean and SEM of
two independent experiments is shown (H3K4me3: Cdk6+/+ versus Cdk6/, *p < 0.05; H3K27me3: Cdk6+/+ versus Cdk6+/++Cdk6, **p < 0.01; Cdk6+/++Cdk6
versus Cdk6/, *p < 0.05).
(F) H3K36me3 ChIP assays were performed using Cdk6+/+ and Cdk6+/++Cdk6 cells. Protein-DNA complexes were immunoprecipitated using an antibody
specific for H3K36me3. ChIP DNAwas analyzed with qPCR for the presence of p16INK4a sequences 1–4, which are depicted as filled black rectangles in the lower
panel (middle of the amplicon relative to the TSS [arrow symbol marked +1] of p16INK4a: 1, 169 base pairs; 2, +538 base pairs; 3, +2,278 base pairs; 4, +4,312
base pairs). The relative enrichment to aGapdh gene body region is shown. The mean and SEM of two independent experiments is shown (sequence 3: Cdk6+/+
versus Cdk6+/++Cdk6, *p < 0.05; sequence 4: Cdk6+/+ versus Cdk6+/++Cdk6, **p < 0.01).
(G) Immunoblot for CDK6 and p16INK4a of Cdk6+/+, Cdk6+/++Cdk6, and Cdk6+/++Cdk6K43M cells.
See also Figure S2.
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CDK6 and Angiogenesiset al., 2009). Consistently, the level of H3K36me3 is signif-
icantly increased: this marker parallels transcriptional activity
(Figure 2F).170 Cancer Cell 24, 167–181, August 12, 2013 ª2013 Elsevier Inc.To investigate whether CDK6 exerts its action on the promoter
by phosphorylation of a hitherto unknown substrate, we tested
whether the kinase-inactivated CDK6 mutant CDK6K43M
Cancer Cell
CDK6 and Angiogenesis(Zacharek et al., 2005) could upregulate p16INK4a. p185BCR-ABL-
transformedCdk6/ and wild-type (WT) cells were infected with
a pMSCV-puro-based retrovirus containing Cdk6K43M to
generate stable cell lines (Figure 2G; Figure S2J). Surprisingly,
upregulation of p16INK4a mRNA and protein is kinase-indepen-
dent (Figure 2G; Figures S2M, S2J, and S2K) and expression
of the mutant CDK6K43M reduces cell growth similarly to
expression of WT CDK6 (Figures S2N and S2L). In line with these
findings, we detected the CDK6K43M mutant at the p16INK4a
promoter (Figure S6I). These experiments indicate the existence
of a kinase-independent function of CDK6 as a transcriptional
regulator of the tumor suppressor p16INK4a.
Inverse Protein Expression Levels of CDK6 and p16INK4a
in Human Tumor Tissue
To examine whether p16INK4a expression accounts for the
growth inhibition caused by CDK6, we expressed CDK6 in
p185BCR-ABL-transformed cells deficient for p16INK4a/p19ARF
(INK4a/ARF/). Those cells showed no growth inhibitory effects
or reduction of leukemogenesis upon enforced CDK6 expres-
sion (Figures 3A and 3B). To substantiate the role of p16INK4a in
a negative feedback loop counteracting high levels of CDK6
expression, we used the CDK6R31C mutant, which is incapable
of binding INK4 proteins (Grossel et al., 1999). Enforced expres-
sion of this mutant should provoke p16INK4a expression but fail to
induce a growth inhibitory effect based on the inability to bind
p16INK4a. Indeed, the reconstitution of p185BCR-ABL-transformed
Cdk6/ andWT cells with a pMSCV-puro-based retrovirus con-
taining Cdk6R31C did not mimic the growth inhibitory effect of
CDK6 despite the presence of high levels of p16INK4a (Figures
S2K–S2P). These experiments confirm that the tumor-suppress-
ing effect of high CDK6 expression results from a negative feed-
back loop mediated by p16INK4a. Accordingly, in the presence of
an intact p16INK4a regulation, there is only a narrow window for
CDK6 acting as growth promoter.
Our model makes a testable prediction: high CDK6 expres-
sion in a lymphoid tumor should confer a growth advantage
only when expression of p16INK4a is disrupted. Support for the
prediction comes from an analysis of patient samples. Levels
of CDK6 and p16INK4a protein were analyzed in two human tis-
sue arrays, one for B cell malignancies, and one for T cell malig-
nancies. Figure 3C compiles three examples of a tissue array
consisting of 16 different cases of B cell lymphoma as well as
a control lymph node. In all cases, we found high levels of
CDK6 expression accompanied by reduced or undetectable
expression of p16INK4a. The tissue array for T cell malignancies
consisted of 28 cases of anaplastic large cell lymphoma (ALCL),
among which 17 carried the NPM-ALK fusion kinase (Figures 3D
and 3E). Because ALCL cells diffusely infiltrate affected lymph
nodes, we used CD30 staining to define the malignant cells.
We found an inverse relationship between CDK6 and p16INK4a
in all samples (Chi-square test, c2 = 11.603, p = 0.02). The
majority of cases had high CDK6 expression and no or scarcely
detectable expression of p16INK4a. However, 4 of 11 NPM-ALK-
negative tumors displayed the opposite phenotype: they had
high p16INK4a levels but lacked immunoreactivity against
CDK6 antibodies (Figure 3E). The correlation was verified by
HistoQuest-assisted analysis (Figures S3A and S3B). The array
experiments revealed an inverse relationship between p16INK4aand CDK6 expression in human B- and T-cell lymphoma
cells, which was confirmed with immunofluorescence staining
(Figure S3C).
The CDK6-p16INK4a Loop in Murine NPM-ALK-Driven
T-Lymphoid Disease
In conjunction with a previous report of AKT-induced thymoma
formation (Hu et al., 2009), our human data indicate a role for
CDK6 not only in B-lymphoid disease, but also in T-lymphoid
tumor formation. In line with the expression data in human
NPM-ALK+ samples, which indicate a key role for CDK6 in
this disease entity, NPM-ALK-transgenic mice lacking Cdk6
developed disease with a significantly prolonged latency and
NPM-ALK+ Cdk6/ cells showed a reduced proliferation
in vitro (Figures 4A and 4B). In cell lines derived from NPM-
ALK+ Cdk6+/+ lymphomas, we found pronounced high CDK6
protein levels. As predicted by our model, this was accompa-
nied by the loss of p16INK4a protein (Figure 4C). The p16INK4a
promoter CpG island was methylated in four of five murine
NPM-ALK+ lymphoma-derived cell lines, indicating that methyl-
ation is responsible for the loss of p16INK4a (Figure 4D). To
assess whether the level of CDK6-enforced expression in
transformed murine cells is comparable to that observed in
human patients, we analyzed levels of CDK6 protein in human
and murine lymphoid cell lines side by side using antibodies
that recognize conserved epitopes of murine and human
CDK6. We found that levels of CDK6 were within the same
range in mice and men (Figures 4E and 4F; Figures
S4A–S4D). In both species, a significant upregulation of
CDK6 protein occurs upon transformation of lymphoid cells
as evident by a side-by-side comparison of transformed versus
nontransformed cells (Figures 4E and 4F). These data led us to
conclude that our model system reflects the situation in human
patients.
Correlation of CDK6 Expression and Tumor
Angiogenesis
Staining 13 human ALCL (11NPM-ALK+ and 2NPM-ALK) sam-
ples for the angiogenic marker CD31 indicated an increased
density of blood vessels in tumors expressing high levels of
CDK6 (Figures S5A and S5B). Additionally, we investigated 33
diffuse large B cell lymphoma (DLBCL) cases for the correlation
of CDK6 expression and blood vessel density (Figures S5C and
S5D). The analysis of the DLBCL samples clearly supports the
notion that CDK6 promotes angiogenesis in hematopoietic
malignancies. To investigate whether CDK6 directly regulates
angiogenesis, we reconstituted Cdk6-deficient p185BCR-ABL-
transformed cells with WT CDK6, CDK6K43M, or CDK6R31C.
Several independently derived cell lines were injected subcuta-
neously into mice and the ability to stimulate angiogenesis was
found to correlate with CDK6 expression, independently of
whether the CDK6 expressed was WT or a mutant version
(Figures 5A and 5B). Tumor growth inversely correlated with
the ability of the CDK6 construct to induce and/or bind to
p16INK4a (Figure 5C). A similar correlation between CDK6 and
angiogenesis could be verified in NPM-ALK+ tumors when we
subcutaneously injected NPM-ALK+ Cdk6/ and NPM-ALK+
Cdk6+/+ cell lines into recipient mice. Cdk6/ tumors evolved
significantly later and displayed severely reduced blood vesselCancer Cell 24, 167–181, August 12, 2013 ª2013 Elsevier Inc. 171
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Figure 3. Inverse Relation between CDK6 and p16INK4a Expression in Human Lymphomas
(A) [3H]thymidine incorporation of Cdk6+/+, INK4a/ARF/, INK4a/ARF/+Cdk6, and INK4a/ARF/+Cdk6R31C p185BCR-ABL-transformed cells (n = 3; Cdk6+/+
versus INK4a/ARF/, **p = 0.002; INK4a/ARF/+Cdk6, **p = 0.001; INK4a/ARF/+Cdk6R31C, **p = 0.005).
(B) Kaplan-Meier plot of Rag2/mice intravenously transplanted withCdk6+/+, INK4a/ARF/, INK4a/ARF/+Cdk6, and INK4a/ARF/+Cdk6R31C cells (n = 3
cell lines/genotype; mean survival: 18 [Cdk6+/+], 15 [INK4a/ARF/], 15 [INK4a/ARF/+Cdk6], and 15.5 [INK4a/ARF/+Cdk6R31C] days; *p = 0.02).
(C) Immunohistochemical stainings of a B cell lymphoma tissue array including 16 lymphoma samples and two control lymph nodes for CDK6 and p16INK4a.
Representative examples including different types of B cell lymphoma, a diffuse large B cell lymphoma (patient A), two follicular lymphomas (patients B and C),
and one control lymph node (left) are depicted. Original magnification 203.
(D and E) The expression of CD30, CDK6, and p16INK4a was analyzed for 17 NPM-ALK-positive (E) and 11 NPM-ALK-negative (D) lymphoma cases with
immunohistochemistry. Representative cases for NPM-ALK-positive (patients D and E) and NPM-ALK-negative (patients F and G) cases are depicted. Original
magnification 203.
Error bars indicate the mean ± SEM. See also Figure S3.
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Figure 4. CDK6 Regulates NPM-ALK-Induced Disease Progression
(A) Cdk6+/+,Cdk6+/, and Cdk6/mice crossed with NPM-ALK transgenic (tg) mice developed a T cell lymphoma after several weeks (nR 8; mean survival 120
[Cdk6+/+], 143.5 [Cdk6+/], and 212 [Cdk6/] days; **p = 0.001).
(B) [3H]thymidine incorporation of NPM-ALK-transformed Cdk6+/+ and Cdk6/ cells (nR 3; *p = 0.009).
(C) Immunoblot for CDK6 and p16INK4a of NPM-ALK-transformed Cdk6+/+ and Cdk6/ cells.
(D) Methylation-specific PCR of a part of the p16INK4a promoter CpG island in NPM-ALK-transformed murine cells. The visible PCR product indicates the
presence of methylated alleles. wt BM, bone marrow of a healthy mouse; pos. contr., control for methylated samples; neg. contr., control for unmethylated
samples.
(E) Immunoblot for CDK6 of untransformed human T cells (three individually derived samples), human T-lymphoid leukemic cell lines (Sudhl1, CCRF, PEER),
untransformed murine T cells (two individually derived samples), murine Cdk6+/+ NPM-ALK-transformed cells, untransformed murine B cells, untransformed
human B cells, and human B-lymphoid leukemic cell lines (SUP-B15).
(F) Immunoblot for CDK6 of untransformed human B cells (three individually derived samples), human B-lymphoid leukemic cell lines (SUP-B15, RL-7, JVM2),
untransformed murine B cells (two individually derived samples), murine Cdk6+/+ p185BCR-ABL-transformed cells (three individually derived cell lines), and murine
Cdk6+/++Cdk6 p185BCR-ABL-transformed cells (three individually derived cell lines).
Error bars indicate the mean ± SEM. See also Figure S4.
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CDK6 and Angiogenesisformation (Figures S5E and S5F). To further confirm the
pro-angiogenic effect of CDK6, we added the cell supernatant
of the Cdk6-deficient p185BCR-ABL-transformed cells expressing
WT CDK6, CDK6K43M or CDK6R31C to murine endothelial
cells. Supernatant from cells expressing CDK6—either WT or
mutant—was capable of significantly stimulating endothelial
cell proliferation, migration, and sprouting (Figures 5D–5G).
Collectively, these data link high CDK6 expression to enforced
tumor angiogenesis.
Transcriptional Regulation of Vegf-A by CDK6
Because tumor angiogenesis is frequently driven by ligands of
the vascular endothelial growth factor (VEGF) receptor, weinvestigated the levels of the most prominent growth factor
VEGF-A (Ferrara and Davis-Smyth, 1997; Neufeld et al., 1999).
Similiar to our observations on the CDK6-mediated control of
p16INK4a, we found that CDK6 induced the expression of Vegf-A
pre-mRNA, mRNA, and protein, irrespective of the mutant used
(Figures 6A and 6B; Figures S6A–S6E). Enforced expression of
CDK4 did not induce Vegf-A and no changes in angiogenesis
could be detected in CDK4-high tumors (Figures S6F–S6H), con-
firming the functional differences between CDK6 and CDK4.
ChIP assays verified CDK6’s role in the regulation of Vegf-A tran-
scription in Cdk6/ p185BCR-ABL-transformed cells expressing
an HA-tagged CDK6 as well as in Cdk6+/++Cdk6 cells (Figures
6C and 6D; Figure S6I). Increased CDK6-induced Vegf-ACancer Cell 24, 167–181, August 12, 2013 ª2013 Elsevier Inc. 173
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Figure 5. CDK6 Regulates Tumor Angiogenesis
(A–C) Cdk6+/+, Cdk6/, Cdk6/+Cdk6, Cdk6/+Cdk6R31C, or Cdk6/+Cdk6K43M p185BCR-ABL-transformed cells were injected subcutaneously (sc) into
Nu/Numice (n = 3 cell lines/genotype; nR 6 tumors/genotype). (A) Immunofluorescence staining for CD31 (red) was performed to analyze blood vessel formation
in sc tumors. Original magnification 203. Representative cases of each genotype are depicted. (B) Quantitative assessment (HistoQuest) of the blood
vessels of the subcutaneous tumors (n R 4 tumors of three independent cell lines; Cdk6/ versus: Cdk6+/+, **p = 0.001; Cdk6/+Cdk6, ***p < 0.0001;
Cdk6/+Cdk6R31C, ***p = 0.0002;Cdk6/+Cdk6 K43M, ***p < 0.0001). (C) Tumor weight was detected after 8 days of injection (Cdk6/ versus:Cdk6+/+, **p =
0.003; Cdk6/+Cdk6R31C, ***p = 0.0001).
(D and E) Murine endothelial cell (mEC) spheroids were cultured in methylcellulose with 20% supernatant derived from indicated cells for 24 hr. (D) Quantita-
tive analysis of the relative sprout length was measured with ImageJ software (n R 3; Cdk6/ versus: Cdk6+/+, *p = 0.042; Cdk6/+Cdk6, **p = 0.002;
Cdk6/+Cdk6R31C, **p = 0.009; Cdk6/+Cdk6K43M, *p = 0.038). (E) One representative set of pictures is given.
(F and G) A monolayer wounding assay was performed to analyze migration of mECs incubated with supernatant derived from indicated cells. After 2 and 24 hr,
pictures were taken and mEC migration quantified (% open area after 24 hr) with TScratch Software. (F) n R 5; Cdk6/ versus: Cdk6+/+, ***p = 0.0007;
Cdk6/+Cdk6, **p = 0.0014; Cdk6/+Cdk6R31C, **p = 0.0092; Cdk6/+Cdk6K43M, ***p = 0.0009). (G) One representative set of pictures is given.
Error bars indicate the mean ± SEM. See also Figure S5.
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Figure 6. CDK6 Regulates Transcription of
the Pro-Angiogenic Factor Vegf-A
(A) Ex vivo VEGF-A protein levels (pg/ml) of the
subcutaneous tumors (see Figures 5A–5C) were
analyzed with an ELISA experiment (n = 3).
(B) Relative Vegf-A mRNA levels of indicated cells
were analyzed by qPCR. The fold change
compared to Cdk6/ Vegf-A mRNA level is
shown (n R 4; Cdk6/ versus: Cdk6/+Cdk6,
***p < 0.0001; Cdk6/+Cdk6R31C, *p = 0.03;
Cdk6/+Cdk6K43M, **p = 0.004).
(C and D) ChIP assays were performed on (C)
Cdk6/ and Cdk6/ cells expressing an HA-
tagged CDK6 using different amounts of an
anti-HA-antibody as well as on (D) Cdk6/ and
Cdk6+/++Cdk6 cells using an anti-CDK6-antibody.
PCRwas performed to detect theVegf-A promoter
sequence.
(E) Dose-response curve of Cdk6+/+ p185BCR-ABL-
transformed cells treated 24 hr with the CDK6/4
inhibitor PD0332991 (n = 3).
(F) Vegf-A mRNA levels of Cdk6+/+ p185BCR-ABL-
transformed cells (n = 3) treated 24 hr with 0, 30,
100, 300, and 1000 nM PD0332991 were analyzed
by qPCR. The fold change compared to untreated
Vegf-A mRNA levels is shown.
(G) p16INK4amRNA levels of Cdk6+/+ p185BCR-ABL–
transformed cells (n = 3) treated 24 hr with 0, 30,
100, 300, and 1,000 nMPD0332991were analyzed
with qPCR. The fold change compared to un-
treated p16INK4a mRNA levels is shown.
Error bars indicate the mean ± SEM. See also
Figure S6.
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CDK6 and Angiogenesistranscription took place via a significant increase in H3K36 trime-
thylation; changes to other histone marks were not statistically
significant (Figures S6J and S6K).
A small molecule inhibitor directed against the ATP binding
pocket domain of CDK4 and CDK6 is currently being tested
in clinical trials (Fry et al., 2004). When we treated cell lines
expressing WT CDK6 with the CDK6/CDK4 inhibitor
(PD0332991), we found a significant reduction of cell prolifera-
tion. In contrast, inhibitor treatment failed to affect the levels
of Vegf-A or p16INK4a mRNA, confirming that CDK6’s role in
transcriptional control is independent of its kinase activity
(Figures 6E–6G).
The regulation of VEGF-A by CDK6 was not restricted to BCR-
ABL+ cells, but was also observed in our T cell lymphomamodel.
NPM-ALK+ Cdk6/ cells showed drastically reduced Vegf-A
mRNA levels compared toNPM-ALK+Cdk6+/+ cells (Figure S6E).
Similarly, the investigation of 23 human B- and T-lymphoid
cell lines revealed the positive correlation between VEGF-A
and CDK6, but not CDK4 mRNA expression levels (Figures
S6L–S6O).Cancer Cell 24, 167–181Interaction Partners of CDK6
STAT and AP-1 transcription factors are
key components for the progression of
BCR-ABL+ leukemia as well as in NPM-
ALK+ lymphomagenesis. Both pathways
are known to regulate expression of
p16INK4a as well as of VEGF-A (Kollmannet al., 2011b; Niu et al., 2002; Passegue´ and Wagner, 2000;
Schmidt et al., 2007; Yin et al., 2009). Co-immunoprecipitation
experiments revealed that CDK6, but not CDK4, is in a complex
with the proto-oncogene STAT3 and the AP-1 transcription fac-
tor c-JUN (Figures 7A and 7B; Figure S7A). To test whether the
transcriptional activity of CDK6 depends on these proteins, we
used p185BCR-ABL-transformed cell lines lacking either c-JUN
or STAT3. CDK6 was capable of inducing VEGF-A expression
in the absence of STAT3, but not in the absence of c-JUN (Fig-
ures 7C and 7D). In contrast, induction of p16INK4a by CDK6
required the presence of STAT3 (Figures 7E and 7F). The findings
were confirmed with ChIP/Re-ChIP studies (Figures 7G, S7B,
and S7C). Recent studies have shown that D-type cyclins have
transcriptional activity (Bienvenu et al., 2010; Despouy et al.,
2003; Musgrove et al., 2011). In our experimental system, cyclin
D2 and cyclin D3 are the interaction partners of CDK4 andCDK6,
while cyclin D1 is not expressed (Figure S7D and data not
shown). ChIP/Re-ChIP experiments confirmed that cyclin D2
and CDK6 are present as a complex at the p16INK4a and the
Vegf-A promoters, and CDK6 is also present at the p16INK4a, August 12, 2013 ª2013 Elsevier Inc. 175
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Figure 7. Transcriptional Interaction Partners of CDK6
(A) An anti-STAT3 co-immunoprecipitation (co-IP) was performed with Stat3D/D, Cdk6/, Cdk6+/+, and Cdk6+/++Cdk6 cell extracts and immunoblotted for
STAT3 and CDK6.
(B) An anti-c-JUN co-IP was performed with c-JunD/D, Cdk6/, Cdk6+/+, and Cdk6+/++Cdk6 cell extracts and immunoblotted for c-JUN and CDK6.
(C and D) Vegf-A mRNA levels of (C) c-JunD/D versus c-JunD/D+Cdk6 and (D) Stat3D/D versus Stat3D/D+Cdk6 p185BCR-ABL-transformed cells were analyzed
with qPCR (nR 3; Stat3D/D versus Stat3D/D+Cdk6: *p = 0.025).
(E and F) p16INK4a mRNA levels of (E) c-JunD/D versus c-JunD/D+Cdk6 and (F) Stat3D/D versus Stat3D/D+Cdk6 p185BCR-ABL-transformed cells were analyzed
with qPCR (nR 3; c-JunD/D versus c-JunD/D+Cdk6: **p = 0.008).
(G) A potential interaction between CDK6 and c-JUN or STAT3 was analyzed in Cdk6+/++Cdk6 cells with ChIP-Re-ChIP experiments at the promoter regions of
Vegf-A and p16INK4a. Antibodies used for ChIP (1st AB) and Re-ChIP (2nd AB) are shown on the right.
(H–K) Vegf-A (H and I) and p16INK4a (J and K) mRNA levels of Cyclin D1/2/3/MEFs versus cyclin D1/2/3/ MEFs enforced expressing CDK6 as well as cyclin
D1/2/3+/+ MEFs versus cyclin D1/2/3+/+ MEFs enforced expressing CDK6 were analyzed with qPCR.
Error bars indicate the mean ± SEM. See also Figure S7.
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Figure 8. Schematic Representation of the Kinase-Dependent and
the Noncanonical Kinase-Independent Functions of CDK6
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CDK6 and Angiogenesispromoter without D-type cyclins (Figures S7E and S7F). Interest-
ingly, CDK6 failed to induce p16INK4a transcription in MEFs defi-
cient for cyclins D1, D2, and D3 (Figures 7H and 7I), but retained
the ability to induce Vegf-A transcription (Figures 7J and 7K). We
failed to detect cyclin D3 at the p16INK4a and the Vegf-A pro-
moters, but can currently not exclude that this is due to the
lack of an antibody suitable for ChIP experiments. In summary,
our data show that CDK6 is contained in transcriptional com-
plexes that include STAT transcription factors and D-type
cyclins. Transcription of different target genes depends on
different members of the complexes. CDK6 may regulate tran-
scription in at least two distinct ways—either in cooperation
with STAT3 and D-type cyclins, e.g., to induce p16INK4a expres-
sion, or together with the AP-1 transcription factor c-JUN, when
it upregulates VEGF-A (Figure 8).
DISCUSSION
CDK6, but not its close homolog CDK4, is frequently expressed
at high levels in human and murine lymphoma and leukemia and
has been proposed to be a driving force for these diseases.
Despite the overwhelming evidence that CDK6 has a unique
role, the underlying mechanism for the preferential upregulation
of CDK6 has remained enigmatic. In this study, we show that
CDK6, in addition to its role as a cell-cycle kinase, has important
kinase-independent functions as a transcriptional regulator. The
nonredundant role of CDK6 in promoting tumors in B and T cell
malignancies is underlined by the strong delay in latency
observed in Cdk6-deficient animals in both NPM-ALK- and
BCR-ABL-driven diseases.
The enforced expression of CDK6 in in vitro-generated
p185BCR-ABL-transformed cell lines unmasked an inhibitory
effect on cell proliferation. On first thought, the result might
appear paradoxical, but our findings can be rationalized bypostulating a feedback loop including the upregulation of the
tumor suppressor and cell-cycle inhibitor p16INK4a. Although
p16INK4a is also able to promote oncogene-induced senescence
(Campisi, 2012), we failed to obtain any evidence of senescence.
CDK4 and CDK6 have recently been shown to counteract the in-
duction of senescence by phosphorylating FOXM1, which may
contribute to the lack of senescence induction (Anders et al.,
2011). Confirmation that p16INK4a is involved in CDK6’s
tumor-suppressing role was obtained from experiments with
p16INK4a/p19ARF-deficient animals and the CDK6R31C mutant
unable to bind INK proteins. CDK6 combines two opposing func-
tions: it is able to inhibit or accelerate cell proliferation depending
on whether p16INK4a is present or not. Levels of CDK6 under
physiologic conditions are confined to a narrow window deter-
mined by these two opposing effects on cell growth.
Accordingly, the requirement for p16INK4a may be regarded as
an internal safeguard that needs to be overcome to allow CDK6
to exert its tumor-promoting function. Malignancies of the B- or
T-lymphoid lineage frequently display loss of p16INK4a due to
deletion, mutation, or methylation (Fizzotti et al., 1995; Hackan-
son et al., 2005; Hebert et al., 1994; Hennessy et al., 2003; Kees
et al., 1997; Malumbres and Barbacid, 2001; Nobori et al., 1994;
Ruas and Peters, 1998). We propose that CDK6 only confers a
proliferative advantage to a transformed cell in the absence of
p16INK4a. Support for this hypothesis is provided by our analysis
of histologic sections of human lymphoid malignancies, which
show an inverse correlation of CDK6 and p16INK4a expression.
Histologic analysis allowed the determination of p16INK4a and
CDK6 expression at the level of individual cells. This is crucial
when studying diseases such as NPM-ALK-driven lymphoma,
in which malignant cells are embedded within a microenviron-
ment containing normal nontransformed lymphoid cells.
Our data predict that enhanced levels of CDK6 protein drive
both cell-cycle progression and angiogenesis. It is currently
unclear what causes the initial upregulation of CDK6 and the
silencing of p16INK4a. It is likely that several events are required,
possibly including aberrant expression of microRNAs, which
have been reported to regulate CDK6 expression. Subsequent
deletion or methylation of p16INK4a may confer a clonal advan-
tage to the cell and induce a selection process that allows the
outgrowth of a distinct CDK6 high p16INK4a-deleted clone. The
ability to promote angiogenesis provides a rationale for the pref-
erential growth of cells that express high levels of CDK6. CDK6 is
not the only factor that promotes blood vessel growth, but it con-
tributes substantially to meeting the tumor’s enhanced demand
for blood supply.
Two important functions have been assigned to cyclin
D/CDK4 (DK4) and cyclin D/CDK6 (DK6) complexes, i.e., phos-
phorylation of the retinoblastoma (Rb) protein and sequestering
of p21Cip and p27Kip1. Both permit progression through the G1
phase of the cell cycle. DK4 and DK6 have been considered
functionally redundant in advancing the cell cycle. However,
CDK6 has recently been proposed to have additional tasks; for
example, it has been implicated in the differentiation of cell types
such as astrocytes and T cells (Ericson et al., 2003; Grossel and
Hinds, 2006; Hu et al., 2009). We speculate that CDK6’s function
in linking growth and differentiation is also (at least partially)
mediated by kinase-independent functions. Multicellular organ-
isms could not have evolved without a linkage between growthCancer Cell 24, 167–181, August 12, 2013 ª2013 Elsevier Inc. 177
Cancer Cell
CDK6 and Angiogenesisand differentiation, so CDK6may be part of a control mechanism
to ensure the generation of complex and fully functional organ-
isms. It is of particular interest that recent findings implicate
D-type cyclins in the link between cell-cycle control, differentia-
tion, and DNA damage repair (Jirawatnotai et al., 2011; Li et al.,
2010). CDK6 and D-type cyclins may even act in concert to link
cell-cycle control to other cellular functions, permitting both
versatility and the possibility of fine-tuning by the inclusion of
components specific for particular stages in the cell cycle.
We are only now starting to understand the importance of the
different roles of cell-cycle regulators, so it is likely that CDK6 has
additional functions in body homeostasis. Uncovering such roles
is hampered by the fact that Cdk6 knockout mice are viable,
although this does not exclude the possibility that the CDK6 pro-
tein may be important under particular circumstances or that the
absence of CDK6 may be compensated for by other factors dur-
ing development. Tumorigenesis is one such condition in which
cell signaling is rewired and previously redundant signaling
pathways assume much greater significance and turn into key
signaling nodes. There is a single report that the CDK6 protein
is part of a complex that binds DNA in an androgen receptor-
dependent manner to enhance transcription of the prostate-spe-
cific antigen in LNCaP prostate cancer cells (Lim et al., 2005).
Our results show that CDK6 is also a component of a transcrip-
tion complex that includes a variety of transcription factors.
CDK6 may act in concert with STAT3 to induce p16INK4a expres-
sion, or with AP-1 transcription factors to upregulate VEGF-A.
Interestingly, VEGF-A regulation seems to be independent of
D-type cyclin binding whereas in the absence of cyclins, CDK6
is unable to induce p16INK4a expression. Although transcription
of different genes requires different factors, our ChIP experi-
ments strongly suggest that all components of the CDK6-
STAT-cyclin D complex are present at all promoters, even if
they are not essential for transcription. Further work will be
required to identify CDK6’s interaction partners in different cell
types and to understand the molecular mechanisms that deter-
mine the importance of the binding of cyclins and other interac-
tion partners for distinct transcriptional targets.
In the absence of p16INK4a, elevated CDK6 levels promote
tumorigenesis. For example, in lymphoma CDK6 induces the
transcription of growth factors such as Vegf-A. Although tumor
growth depends on angiogenesis, there are few indications of
factors involved in the regulation of both processes. The mech-
anism underlying their interdependence has thus remained
elusive. Because CDK6 promotes tumor growth while simulta-
neously guaranteeing the supply of oxygen and energy to the
rapidly growing tumor, it enables tumor cells to proliferate
extremely efficiently.
Considerable effort has been expended on targeting angio-
genesis for the treatment of tumors. These methods suffer
from the potential limitation that they may promote the appear-
ance of highly malignant metastatic subclones that evolve under
hypoxic pressure resulting from treatment with angiogenic inhib-
itors. A targeted therapy against CDK6, simultaneously inhibiting
growth and angiogenesis, may represent a unique opportunity to
overcome the detrimental effects. CDK6 kinase activity already
represents a promising target for anticancer drugs (Choi et al.,
2012; Sawai et al., 2012). In light of our findings, it is important
that future drug design take into account the kinase-independent178 Cancer Cell 24, 167–181, August 12, 2013 ª2013 Elsevier Inc.function of the CDK6 protein. Because CDK6 knockout mice are
viable, such inhibitors should have high antitumor effects and be
specific for tumorigenesis. Our findings also suggest that CDK6-
directed therapies may be useful for Rb deficient tumors that do
not rely on the cell cycle effects of CDK4/CDK6 complexes.
EXPERIMENTAL PROCEDURES
Mice
All mice were on a C57BL/6 background. Cdk6/ (Malumbres et al., 2004),
INK4a/ARF/ (Serrano et al., 1996), NPM-ALK-tg (Chiarle et al., 2003),
Nu/Nu, and Rag2/ mice (Shinkai et al., 1992) have been described previ-
ously. Animal experiments were performed in accordance with protocols
approved by the Animal Welfare Committee at the Medical University of
Vienna.
Handling of Human Subjects
The B-lymphoid tissue array was obtained from the Institute of Pathology, Uni-
versity Hospital Graz. The T-lymphoid tissue array was obtained from the
Department of Clinical Pathology, University of Vienna and was established
using samples from patients with anaplastic large cell lymphoma (NPM-ALK
positive and NPM-ALK negative). Human peripheral blood samples were
recruited for this study from the NHS blood and transplant (NHSBT) in
Cambridge, UK. Samples were obtained after informed consent in compliance
with the Declaration of Helsinki. All samples were de-identified prior to
analysis.
Monolayer Wounding Assay
In this assay, 13 105murine endothelial cells (mECs) were seeded in endothe-
lial cell growth medium (RPMI containing 10% fetal calf serum (FCS) mixed 1:1
with Epithelial Cell Growth Medium MV (PromoCell). After 24 hr, medium was
removed and a scratchmade through themonolayer. Cells were washed twice
with PBS and covered with supernatants as appropriate.
For supernatant production, a defined cell number of different cell lines was
incubated in medium for 24 hr. Supernatant was collected and filtered to
remove leukemic cells.
After 2- and 24-hr incubation of mECs with the supernatants, pictures of the
scratch were taken under a microscope (Nikon, Eclipse TS100; 103) using a
digital camera (Nikon, Coolpix P5000; Zoom F2.7). To analyze migration differ-
ences, the percentage of the open area of the scratch was measured with
TScratch software.
Spheroid Sprouting Assay
mECs were suspended in 80% endothelial cell growth medium (RPMI contain-
ing 10% FCS mixed 1:1 with Epithelial Cell Growth Medium MV (PromoCell)
and 20%methylcellulose (Sigma) and seeded as drops (800 cells/30 ml) in non-
adherent dishes. The disheswere incubated upside down as hanging drops for
24 hr. Under these conditions, all suspended cells contribute to the formation
of a single spheroid per drop of defined size and cell number (800 cells/
spheroid). Spheroids were harvested and seeded in methylcellulose and
supernatant (prepared as described under Monolayer Wounding Assay) of
the leukemic cells was added. After 24-hr incubation, the cumulative length
of the sprouts from each spheroid was measured with ImageJ software.
ChIP and Re-ChIP Assays
ChIP assays were performed using the chromatin immunoprecipitation assay
kit (Upstate Biotechnology) according to the manufacturer’s protocol: 53 106
cells were treated with 1% formaldehyde for 10min and then lysed. Chromatin
was sheared to 200–1,000 bp fragments using Bioruptor (Diagenode). The an-
tibodies are given in the Supplemental Experimental Procedures. Nonrelated
IgG (10 mg) was used as a control. Immunoprecipitated DNAwas phenol-chlor-
ophorm-extracted, ethanol-precipitated, and dissolved in 30 ml Tris-EDTA (TE)
buffer. Twomicroliters of recovered DNA were used for subsequent PCR anal-
ysis. Primer sequences for p16INK4a, ARF, and Vegf-A promoter and PCR con-
ditions were as reported previously (Gonzalez et al., 2006; Ray et al., 2007).
PCR products were separated on a 2% agarose gel stained with GelRed
(Biotium).
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CDK6 and AngiogenesisFor Re-ChIP experiments, 13 108 cells were lysed and chromatin-sonicated
as described above. After immunoprecipitation with the first antibody, protein-
DNA complexes were eluted from protein A-agarose beads by incubation for
30 min at 37C in 50 ml of elution buffer (13 TE, 15% dithiothreitol, and prote-
ase inhibitors). The second immunoprecipitation was performed as described
above.
Statistical Analysis
Data are reported as mean values ± SEM. Biochemical experiments were
performed in triplicate and a minimum of three independent experiments
were evaluated. Differences were assessed for statistical significance by an
unpaired two-tailed t test, by the log rank test (for Kaplan-Meier plots), or by
the c2-square test (for contingency tables). The p values are considered as
follows: *p < 0.05; **p < 0.01; and ***p < 0.001.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and seven figures and can be found with this article online at http://dx.doi.
org/10.1016/j.ccr.2013.07.012.
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